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Abstract
Background: Numerous DNA-damaging cellular stresses, including oncogene activation and DNA-damage response
(DDR), may lead to cellular senescence. Previous observations linked microRNA deregulation with altered senescent
patterns, prompting us to investigate whether epigenetic repression of microRNAs expression might disrupt senescence
in prostate cancer (PCa) cells.
Methods: Differential methylation mapping in prostate tissues was carried using Infinium HumanMethylation450
BeadChip. After validation of methylation and expression analyses in a larger series of prostate tissues, the functional
role of the cluster miR-130b~301b was explored using in vitro studies testing cell viability, apoptosis, invasion and DNA
damage in prostate cancer cell lines. Western blot and RT-qPCR were performed to support those observations.
Results: We found that the miR-130b~301b cluster directs epigenetic activation of cell cycle inhibitors required for DDR
activation, thus stimulating the senescence-associated secretory phenotype (SASP). Furthermore, overexpression of miR-
130b~301b cluster markedly reduced the malignant phenotype of PCa cells.
Conclusions: Altogether, these data demonstrate that miR-130b~301b cluster overexpression might effectively induce
PCa cell growth arrest through epigenetic regulation of proliferation-blocking genes and activation of cellular
senescence.
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Background
MicroRNAs (miRNAs) are small, non-coding RNAs that
act as sequence-specific guides for Argonaute (AGO)
proteins, which mediate post-transcriptional silencing of
target mRNA [1]. miRNAs are transcribed from individual
genes containing their own promoters or are originated
intragenically from spliced segments of other genes [2].
They contain upstream regulatory elements and pro-
moter regions, indicating that miRNAs might endure
CpG promoter methylation via DNA methyltransferase
(DMNT), histone modifications, as well as other regula-
tory alterations [1, 3]. Importantly, whereas miRNA genes
transcription-start sites (TSS) are occasionally 5–10 kb
away from the pre-miRNA sequence [4], promoter regions
may be up to 50 kb apart, which may preclude the eluci-
dation of transcriptional regulation of particular miRNAs
[1]. Functional miRNAs result from sequential processing
of pri-miRNAs by RNase III family enzymes DROSHA
(nucleus) and DICER (cytoplasm). Unlike their protein-
coding counterparts, however, miRNAs function as guides
for identifying target mRNAs for repression [5].
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MiRNAs are involved in development, homeostasis,
cell cycle, apoptosis and in diverse pathological condi-
tion in nearly all vertebrate tissues [6]. Importantly,
aberrant miRNA expression levels have been associated
with promotion or arrest of tumorigenesis, through its
ability to control the expression of a myriad of protein-
coding and non-coding genes [7]. Concordantly, deregu-
lation of miRNA expression has been reported in several
malignancies, including prostate cancer (PCa) [3]. PCa is
currently the most common non-cutaneous malignancy
in developed countries and the second leading cause of
death from cancer in men in the USA and in Europe,
accounting for one in nine of all newly diagnosed can-
cers in men [8]. Nonetheless, altered miRNA expression
patterns in PCa have been significantly understudied
compared to other cancers, despite evidence suggesting
a global downregulation of miRNA expression in both
tumorigenesis and treatment resistance [9, 10].
Here, we examined how epigenetic alterations might
contribute to miRNAs deregulation in PCa, focusing on
the role of miR-130b~301b cluster. We found that miR-
130b~301b cluster displays tumour-suppressive functions
in vitro, influencing cell cycle, cell viability, apoptosis and
invasion. Interestingly, an unprecedented effect of miR-
130b~301b cluster on cellular senescence, which prevents
cancer cell proliferation, was disclosed, suggesting that
impairment of cellular senescence might underlie the
deleterious effects of miR-130b~301b cluster downregula-
tion in prostate carcinogenesis.
Methods
Patients and sample collection
Primary tumour tissues from 111 patients harbouring
clinically localized PCa were prospectively collected,
after diagnosis and primary treatment with radical pros-
tatectomy at Portuguese Oncology Institute of Porto,
Porto, Portugal (Additional file 1: Table S1). A set of 14
morphologically normal prostate tissues (MNPT) was
procured from prostatic peripheral zone of bladder can-
cer patients submitted to cystoprostatectomy and which
did not harbour concomitant PCa. All tissue specimens
were promptly frozen after surgery. Upon histological
confirmation of tumour or normal prostate tissue, fresh-
frozen tissue fragments were trimmed to enhance yield
of target cells (>70%). Histological slides from formalin-
fixed paraffin-embedded tissue fragments were also rou-
tinely obtained from the surgical specimens and assessed
for Gleason score and TNM stage. Relevant clinical data
was collected from clinical charts and informed consent
was obtained from all participants, according to institu-
tional regulations. This study was approved by the insti-
tutional review board (Comissão de Ética para a Saúde)
of Portuguese Oncology Institute of Porto, Portugal
(CES-IPOPFG-EPE 205/2013).
Nuclei acid extractions, bisulfite conversion and cDNA
synthesis
DNA from fresh frozen tissue samples and cell lines was
extracted using phenol:chloroform (Sigma). RNA was
obtained using TRIzol (Invitrogen, Carlsbad, CA, USA)
according to manufacturer’s instructions.
Bisulfite conversion of 1000 ng of genomic DNA was
accomplished using EZ DNA Methylation Kit (Zymo
Research), following manufacturer’s instructions.
Specific-miRNA cDNA was obtained using TaqMan
MicroRNA Reverse Transcription Kit from Applied Bio-
systems (Foster City, CA, USA). Total cDNA synthesis
was performed using high-capacity cDNA Reverse Tran-
scription Kit (Applied Biosystems).
Infinium HumanMethylation450 BeadChip
All DNA samples were assessed for integrity, quantity
and purity by electrophoresis in a 1.3% agarose gel, pico-
green quantification and nanodrop measurements. All
samples were randomly distributed into 96-well plates.
Bisulfite-converted DNA (200 ng) were used for
hybridization on the HumanMethylation450 BeadChip
(Illumina), comprising 25 PCa and 5 MNPT.
HumanMethylation450 BeadChip data were processed
using Bioconductor minfi package [11]. The “Ilumina”
procedure, which mimics the method of GenomeStudio
(Illumina), was performed comprising background cor-
rection and normalization taking the first array of the
plate as reference. Probes with one or more single-
nucleotide polymorphisms (SNPs) with a minor allele
frequency (MAF) >1% (1000 Genomes) in the first 10 bp
of the interrogated CpG were removed. The methylation
level (β) for each of the 485,577 CpG sites was calculated
as the ratio of methylated signal divided by the sum of
methylated and unmethylated signals, multiplied by 100.
After normalization step, probes related to X and Y
chromosomes were removed. All analyses were per-
formed in human genome version 19 (hg19), and data
was deposited in GEO repository under accession num-
ber GSE52955.
Pyrosequencing
Specific sets of primers for PCR amplification and
sequencing were designed using a specific software pack
(PyroMark assay design version 2.0.01.15). Primer se-
quences were designed to hybridize, whenever possible,
with CpG-free sites, ensuring methylation-independent
amplification. PCR was performed under standard con-
ditions with biotinylated primers, and the PyroMark
Vacuum Prep Tool (Biotage, Uppsala, Sweden) was used
to prepare single-stranded PCR products according to
manufacturer’s instructions. Pyrosequencing reactions
and methylation quantification were performed in a
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PyroMark Q96 System version 2.0.6 (QIAGEN) using
appropriate reagents and recommended protocols.
RT-qPCR
MiRNA transcript levels were assessed using TaqMan
MicroRNA Assays specific for each miRNA (miR-130b,
assay ID: 000456; miR-301b, assay ID: 002392) and
normalized with RNU48 (assay ID: 001006; Applied
Biosystems).
Real-time quantitative PCR (RT-qPCR) analysis was
performed using gene-specific primers (Additional file 1:
Table S2) and normalized to the expression of GUSB
housekeeping gene.
PCa cell lines
LNCaP cells were grown in RPMI 1640, DU145 cells
were maintained in MEM and PC-3 cells were grown in
50% RPMI-50% F-12 medium (GIBCO, Invitrogen,
Carlsbad, CA, USA). All basal culture media were sup-
plemented with 10% fetal bovine serum and 1% penicil-
lin/streptomycin (GIBCO, Invitrogen, Carlsbad, CA,
USA). Cells were maintained in an incubator at 37 °C
with 5% CO2. All PCa cell lines were routinely tested for
Mycoplasma spp. contamination (PCR Mycoplasma
Detection Set, Clontech Laboratories).
To reverse DNA methylation effect in the cell lines, we
used 1 μM of the DNA methyltransferases inhibitor 5-aza-
2-deoxycytidine (5-Aza-CdR; Sigma-Aldrich, Schnelldorf,
Germany) alone or in combination 0.5 μM histone deace-
tylase inhibitor trichostatin A (TSA; Sigma-Aldrich,
Schnelldorf, Germany). After 72 h, cells were harvested
and RNA extracted.
Pre-miRNA and anti-miRNA transfections
To inhibit miR-130b and miR-301b, single-stranded
nucleic acids designed to specifically bind and inhibit
endogenous miRNA (miR-130b Inhibitor, product ID:
AM10777; miR-301b Inhibitor, product ID: AM12929,
Ambion) were used. Anti-miR-130b and Anti-miR-301b
were transfected as follows: in LNCaP, 25 and 50 nM,
respectively; DU145, each at 50 nM; and PC3, 50 and
70 nM, respectively.
MiR-130b and miR-301b overexpression were accom-
plished through commercially available synthetic precursor
miRNAs (pre-miR-130b, product ID: PM10777; pre-miR-
301b, product ID: PM12929, Ambion), each transfected at
20 nM. Transfections were performed using Oligofecta-
mine (Invitrogen), per manufacturer instructions.
Viability assay
Cell viability was evaluated by MTT assay. Briefly, PCa
cells were seeded onto 96-well flat bottomed culture
plates, allowed to adhere overnight and transfected 24 h
later (number of cells plated before transfection: LNCaP:
10000 cells/well; DU145: 4000 cells/well; PC3: 3000
cells/well in 96-well plates). At each time point, 0.5 mg/
ml of MTT reagent [3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl-tetrazolium bromide] was added to each well,
and the plates were incubated in the dark for 1 h at 37 °
C. Formazan crystals were then dissolved in DMSO and
absorbance was read at 540 nm in a microplate reader
(FLUOstar Omega, BMG Labtech, Offenburg, Germany),
subtracting the background, at 630 nm. Three replicates
for each condition were performed, and at least three
independent experiments were carried out. Measure-
ments were performed 24, 48 and 72 h post-miRNA
manipulation.
Apoptosis evaluation
Evaluation of apoptosis was performed using APOPer-
centage apoptosis assay kit (Biocolor Ltd., Belfast,
Northern Ireland) according to the manufacturer’s in-
structions. PCa cells were seeded onto 24-well plates
(LNCaP: 50,000 cells/well, DU145 and PC3: 30,000 cells/
well) and 24 h later were transfected. Apoptotic cells
were assessed at the end of day 3 (72 h after transfec-
tion), in a FLUOstar Omega microplate reader at
550 nm and the background subtracted at 620 nm. The
results were normalized to number of viable cell deter-
mined in MTT assay according to the following formula:
OD of apoptosis assay at 72 h/OD of MTT at 72 h.
Cell cycle analysis
Cell cycle distribution of PC3 cells was determined by
flow cytometry. Briefly, 72 h after transfection (150,000
cells/well at day 0, in 6-well plates), 5 × 105 harvested
cells were fixed overnight at 4 °C with 70% cold ethanol.
After washing with cold PBS, cells were re-suspended in
Propidium Iodide Solution (Cytognos S.L, Salamanca,
Spain) and incubated for 30 min at room temperature.
All cells were then measured on a Cytomics FC500 flow
cytometer (Beckman Coulter, Fullerton, CA, USA) and
analysed using Modfit LT (Verity Software House, Inc.,
Topshan, ME, USA).
Single cell gel electrophoresis (comet assay)
Seventy-two hours after transfection (150,000 cells/well
at Day 0, in 6-well plates), 50,000 cells were harvested
by trypsinization, washed in PBS and re-suspended in
75 μl of low-melting point agarose (Invitrogen, Carlsbad,
CA, USA). This suspension was then applied on top of
the base layer consisting of normal-melting point agar-
ose in a slide, after which it polymerized for 10 min at
4 °C. The slides were then immersed in lysis solution
(2.5 M NaCl, 100 mM Na2EDTA, 10 mM Tris Base and
1% Triton X-100) at 4 °C during 2 h in the dark. To
allow DNA to unwind, slides were posteriorly incubated
in an alkaline electrophoresis buffer (300 mM NaOH,
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1 mM Na2EDTA, pH= 13) for 40 min at 4 °C. Electrophor-
esis was accomplished on a horizontal electrophoresis plat-
form at 4 °C for 20 min at 15 V. Subsequently, they were
incubated in a neutralization buffer (Tris–HCl; pH = 7.5)
for 10 min. After fixation with 100% ethanol, slides were
stained with Sybr Green® (Life Technologies, Foster City,
CA, USA) and DNA damage was evaluated under a fluor-
escent microscope. At least three independent experiments
were performed for each condition. The DNA damaging
effect in terms of DNA fragmentation was determined by
measuring four parameters, that included tail moment, tail
length, percentage of DNA in tail of the comet, and 50
DNA-damaged cells were counted at least, for each
condition.
Cell invasion assay
Cell invasion was determined using BD BioCoat Matrigel
Invasion Chamber (BD Biosciences, Franklin Lakes, NJ,
USA). Both cell lines were transfected with miRNA mol-
ecules for 72 h. Then, 5 × 104 cells/mL of PC3 cells were
added to the upper chamber. After 44 h (LNCaP) or
20 h (PC3), the membrane bottom containing invading
cells was fixed in methanol, washed in PBS and stained
with DAPI (Vector Laboratories, Burlingame, CA). All
invading cells were counted under a fluorescence micro-
scope. Three independent experiments were performed
for each condition.
Transcriptomic evaluation of altered genes following
cluster miR-130b~301b manipulation
Cells (LNCaP: 400,000 cells/well, DU145: 200,000 cells/
well and PC3: 150,000 cells/well) were plated in 6-well,
in the day before transfection. Cells were collected 72 h
post-transfection and RNA was extracted and used as
template for cDNA synthesis. RT-qPCR was performed
as previously described.
Western blot
One hundred fifty thousand cells per well were plated
before transfection; 72 h post-transfection, cell lysates
were separated on 4–20% Mini-PROTEAN TGXPrecast
Gel at 120 V and transferred onto PVDF membrane
using semi-dry transfer. The membrane was incubated
for 1 h in blocking buffer (5% non-fat dry milk) and
incubated 2 h, at room temperature, with primary anti-
bodies (Additional file 1: Table S3). Blots were developed
using Immun-Star WesternC Chemiluminescent kit
(Bio-Rad, Hercules, CA, USA).
Morphometric analysis
Cell morphology was examined 72 h after transfection
using a digital camera connected with Olympus phase-
contrast microscope. The cell area and sphericity were
determined with the Olympus cellSens Dimension
software (Olympus Corporation, Shinjuku, Japan) using
the freehand polygon tool.
TCGA data in prostate cancer patients
Data on mRNA expression and clinical information
(when available) from PCa and matched normal patient
samples deposited in The Cancer Genome Atlas (TCGA)
was retrieved. mRNA expression data from samples
hybridized at University of North Carolina, Lineberger
Comprehensive Cancer Center, using Illumina HiSeq
2000 mRNA Sequencing version 2, were downloaded
from TCGA data matrix (https://gdc-portal.nci.nih.gov/
projects/TCGA-PRAD), including 497 PCa and 52
matched normal [12]. To prevent duplicates, when there
was more than one portion per patient, median values
were used. The provided value was pre-processed and
normalized according to ‘level 3’ specifications of TCGA
(see https://gdc-portal.nci.nih.gov/ for details). Clinical
data of each patient was provided by Biospecimen Core
Resources (BCRs). Data is available for download
through TCGA data matrix (https://gdc.cancer.gov/gdc-
tcga-data-access-matrix-users).
Statistical analysis
For group comparisons analysis, non-parametric tests
(Kruskal-Wallis and Mann-Whitney U test) were used.
For in vitro assays, comparisons between two groups
were performed using the Mann-Whitney U test. Data
are shown as mean ± s.d., unless otherwise specified. Stu-
dent’s t tests were used for invasion assays. All statistical
tests were two-sided. Statistical analysis was carried out
using Graph Pad Prism version 5. Significance level was
set at p < 0.05.
Results
Identification of a miRNAs subset targeted by DNA
methylation in prostate cancer
We sought to identify specific differentially methylated
miRNA loci between PCa and MNPT (Additional file 2:
Figure S1A). The DNA methylation analysis was con-
ducted using the Infinium HumanMethylation450 Bead-
Chip (450 k array), a high-density DNA methylation
array that interrogates ≈485,000 human CpGs. A total of
439 CpG sites located in miRNA gene promoter regions
were found to be differentially methylated and were
clustered separately (non-parametric Mann-Whitney
and Wilcoxon matched pair test were applied). For all
analyses, p values inferior to 0.05, after FDR correction,
were considered statistically significant (Fig. 1a; Table 1;
Additional file 2: Figure S1A). Thus, 51 differentially
methylated miRNA promoters in PCa were identified
(Fig. 1a, Additional file 2: Figure S1B) and mapped to 19
chromosomes. Chromosomes 19 (n = 6), 11 and 7 (n = 5)
and 2 (n = 4) were the most enriched genomic locations
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for differential methylation (Additional file 2: Figure S1C).
Simultaneously, we identified several hypomethylated can-
didates, including miR-181c~181d and miR-449a~449b
clusters. In the hypermethylated branch, our dataset
disclosed previously unreported miRNA-promoters, in-
cluding miR-130b~301b cluster, miR-149, miR-212, miR-
10a, miR-152, miR-210 and miR-129-2. Consistent with
previous observations, we confirmed hypermethylation of
miR-193b, miR-9 family and miR-34b-34c cluster
(Additional file 2: Figure S1B). Gene Ontology (GO,
Additional file 1: Table S4) revealed that putative tar-
gets of this subset of miRNAs dynamically regulated
by DNA methylation are involved in critical pathways
including ‘sister chromatid segregation’, ‘regulation of
double-strand break repair’, ‘posttranscriptional gene
silencing by RNA’, ‘regulation of adaptive immune re-
sponse’, ‘G1 DNA damage checkpoint’ or ‘DNA-templated
transcription’. Strikingly, GO analysis also disclosed that
the putative targets of this miRNA panel were also
involved in ‘hippo signalling’ and ‘prostate gland growth’,
indicating a critical role in normal prostate biology. Based
on β-values for DNA methylation levels, miR-130b~301b
cluster ranked first (Table 1) and was selected for subse-
quent validation in a larger cohort.
Fig. 1 Differentially methylated microRNAs in prostate cancer. a Unsupervised hierarchical clustering of microRNAs’ promoters displaying significant
alterations in DNA methylation as determined by Infinium HumanMethylation450 BeadChip in 25 prostate cancer (PCa) and 5 morphologically normal
prostate tissue (MNPT) samples. Overall, 51 miRNA promoters were differentially methylated in PCa versus MNPT. b Validation of miR-130b~301b by
pyrosequencing and (c) by RT-qPCR in 111 primary PCa and 14 MNPT cases, indicated that promoter hypermethylation was associated with miR-
130b~301b downregulation. d LNCaP, DU145 and PC3 cell lines retain basal expression of miR-130b and miR-301b. e Reversal of DNA methylation in
LNCaP cells using 5-aza-2-deoxycytidine (5-AZA-CdR) increased the expression of miR-130b and, in combination, with TSA augmented miR-301b
expression. Mann-Whitney U test: *p < 0.05, **p < 0.01, ***p < 0.001
Table 1 Top 10 of differentially methylated miRNAs in prostate cancer
CHR miRNA Coordinates (GRCh37.p5) RELATION
CPG ISLAND
miRBase/MirgeneDB
[34]
Gene
family
Clustered
miRNA
Methylation
frequency (array)
22 MIR130B;MIR301B chr22: 22007593-22007674 [+] S_Shore Ok/ok MIR130 MIR301B/130B 0.76
17 MIR152 chr17: 46114527-46114613 [−] Island Ok/ok MIR148 0.72
2 MIR1258 chr2: 180725563-180725635 [−] S_Shore Ok/– MIR1258 0.68
16 MIR762 chr16: 30905224-30905306 [+] N_Shore Ok/– MIR762 0.52
11 MIR34B;MIR34C chr11: 111384164-111384240 [+] Island Ok/ok MIR34 MIR34B/34C 0.44
15 MIR9-3 chr15: 89911248-89911337 [+] N_Shore Ok/ok MIR9 0.44
1 MIR9-1 chr1: 156390133-156390221 [−] N_Shore Ok/ok MIR9 0.36
11 MIR129-2 chr11: 43602944-43603033 [+] Island Ok/ok 0.36
6 MIR219-1 chr6: 33175612-33175721 [+] N_Shore Ok/ok MIR219 0.32
11 MIR210 chr11: 568089-568198 [−] Island Ok/ok MIR210 0.32
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Validation of HumanMethylation450 BeadChip by
pyrosequencing
Validation of miR-130b~301b cluster results was accom-
plished through pyrosequencing, which confirmed that
promoter methylation levels were significantly higher in
PCa compared to MNPT (Fig. 1b). Likewise, PCa cell
lines DU145, LNCaP and PC3 also demonstrated miR-
130b~301b promoter methylation (Additional file 2:
Figure S1D).
DNA methylation associates with miR-130b~301b cluster
expression
MiR-130b~301b cluster expression levels were evaluated
in a series of 125 prostate tissue samples, using RT-
qPCR, and were found to be significantly downregulated
in PCa (p < 0.0001 for miR-130b; p = 0.0014 for miR-
301b, Fig. 1c) compared to MNPT. Then, the effect of
demethylating drugs was tested, as the PCa cell lines still
displayed endogenous expression of miR-130b and miR-
301b (Fig. 1d). In LNCaP cells, miR-130b was significantly
upregulated after exposure to 5-Aza-CdR, whereas miR-
301b was only re-expressed upon combined treatment
with 5-Aza-CdR and TSA (Fig. 1e).
Functional impact of miR-130b~301b cluster expression
manipulation in vitro
The phenotypic impact of altered miR-130b~301b clus-
ter expression was assessed in PCa cell lines in which
miR-130b~301b cluster expression was detected along
with promoter methylation: LNCaP, DU145 and PC3
(Additional file 2: Figure S1D).
The impact of endogenous miR-130b~301b blockage
was firstly assessed, and the efficiency of silencing was
confirmed by RT-qPCR (Additional file 2: Figure S2). In
LNCaP cells, anti-miR-130b significantly enhanced
growth rate at 72 h (Fig. 2a, p < 0.001), whereas anti-miR-
301b showed no significant effect. Conversely, at 72 h
post-transfection, apoptosis was only decreased in anti-
miR-130b transfected LNCaP cells (Fig. 2d, p = 0.0043).
Importantly, decreased CASP3 expression levels (Fig. 2f)
were consistent with reduced apoptosis. Interestingly, in
LNCaP cells, miR-301b knockdown significantly increased
invasion capacity. However, for miR-130b silencing, no
significant differences were apparent, suggesting that miR-
130b is more likely implicated in invasion regulation than
miR-301b. In DU145 cells, inhibition of either miRNA
significantly increased cell viability (Fig. 2b, p < 0.001 for
both). Interestingly, the effect of anti-miR-130b was
already apparent at 48 h upon transfection (p < 0.0001).
Although decreased apoptosis was depicted for both
conditions, it only reached statistical significance in anti-
miR-301b transfected cells (Fig. 2d, p = 0.0022). A slight
increase in Ki67 mRNA expression was found upon anti-
miR-130b transfection (Fig. 2g, p = 0.026). Thus, in
DU145 cells, miR-301b seems to be more critical than
miR-130b, although the latter might influence cell viabil-
ity. MiR-130b or miR-301b inhibition in PC3 cells dramat-
ically enhanced cell viability (Fig. 2c, p < 0.001). Moreover,
increased proliferation was complemented with a signifi-
cant decrease in apoptosis after anti-miR-130b or anti-
miR-301b transfection (Fig. 2d). Remarkably, an apparent
effect on cell invasion was observed for miR-130b~301b
depleted PCa cells, reaching statistical significance in miR-
301b-depleted LNCaP cells (Fig. 2e).
Because phenotypic changes were more apparent in
PC3 cells, these were selected for evaluation of expression
of several genes involved in relevant signalling pathways.
Thus, a significant decrease in CASP8, CASP9, CDKN1A
and CDKN1B expression was depicted, whereas CASP3
and Ki67 mRNA levels remained unaltered (Fig. 2h).
Moreover, a significant reduction in CD44 and p27 ex-
pression was also observed, in line with the invasive
phenotype induced by anti-miR-130b and anti-miR-301b
transfection in PC3 cells (Fig. 2h,i).
MiR-130b~miR-301b overexpression attenuates the
malignant phenotype and promotes MET
The phenotypic impact of miR-130b or miR-301b overex-
pression was tested in PC3 cells. A marked reduction in
cell viability (Fig. 3a) and increased apoptosis (Fig. 3b),
along with increased caspases expression, especially
CASP8 (Fig. 3e), was observed. Cell cycle analysis by flow
cytometry depicted a significant arrest at S phase follow-
ing miR-130b or miR-301b overexpression and at G2/M
phase after miR-130b overexpression (Fig. 3c). These
phenotypic alterations were further confirmed by signifi-
cant decrease in Ki67 expression and increased CDKN1A
(p21) and CDKN1B (p27) expression, both at mRNA and
protein level (Fig. 3e, f ). In the TCGA dataset, these
findings were confirmed at mRNA level for CDKN1A
(p < 0.01), but not for CDKN1B, (Additional file 2:
Figure S3), whereas Ki67 was strongly up-regulated in
PCa samples (p < 0.0001), as expected. Collectively,
these observations indicate that decreased cell viabil-
ity results from a combined effect of cell cycle arrest
and increased apoptosis.
We then hypothesized that miR-130b~301b cluster
might inhibit epithelial to mesenchymal transition
(EMT) and/or facilitate mesenchymal to epithelial tran-
sition (MET) in PCa cells. PC3 cells possess a more
mesenchymal-like gene expression profile [13] and
phenotype. Moreover, the capacity of cancer cells to mi-
grate and invade is an important requirement for metas-
tasis formation, and both are EMT hallmarks. With this
in mind, the effect of miR-130b~301b expression on
PC3 cells migration was assessed. Restoration of miR-
130b~301b impaired the invasive capacity of PC3 cells
(Fig. 3d), whereas the opposite was observed following
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miR-130b~301b depletion (Fig. 2e). Moreover, miR-
130b~301b overexpression was associated with increased
CD44 expression, both at mRNA and protein level
(Fig. 3e,f ), whereas inhibition of miR-130b or miR-301b
decreased CD44 expression (Fig. 2h,i). The expression of
other genes implicated in EMT was also assessed
(Additional file 2: Figure S4) and a differential impact
of miR-130b and miR-301b was suggested.
Moreover, miR-130b or miR-301b overexpression
caused a shift in PC3 cell morphology towards a more
epithelial-like phenotype, compared to wild-type PC3
cells or those with miR-130b or miR-301b depletion,
which are more spindled (i.e., more mesenchymal-like,
Additional file 2: Figures S4 and S5). These findings
suggest that miR-130b and miR-301b facilitate MET,
impairing cell migration and invasion.
Cluster miR-130b~301b induces senescence in PC3 cells
Cellular senescence is a process by which proliferation-
competent cells undergo growth arrest, in response to
various cellular stresses. Because miR-130b and miR-
301b were able to induce cell cycle arrest and decreased
cell viability, along with CDKN1A and CDKN1B overex-
pression and Ki67 downregulation, a link with cellular
senescence was suggested.
Because senescent cells undergo cell size increase, this
characteristic was evaluated upon miR-130b or miR-
301b re-expression in PC3 cells. Morphometric analysis
(Additional file 2: Figure S5) disclosed a significant
increase in cell area (approximately 50%), compared to
scramble cells (Fig. 4a, p < 0.0001), with a significant
increase in sphericity, as well (p < 0.0001, Fig. 4b). Con-
versely, a significant decrease in cell area was apparent
when endogenous miR-130b or miR-301b were depleted
(Fig. 4c; Additional file 2: Figure S6), whereas a signifi-
cant decrease in sphericity was depicted for miR-130b
only (Fig. 4d, Additional file 2: Figure S6). Then, expres-
sion of other senescence-associated genes was evaluated.
Transfection of miR-130b or miR-301b was associated
with significant upregulation of tumour suppressor
Fig. 2 Phenotypic effects induced by blocking endogenous levels of miR-130b or miR-301b in PCa cell lines. a–c Cell viability measured by MTT
assay at different time points and (d) apoptosis evaluation 72 h post-transfection for LNCaP, DU145 and PC3 cells, respectively, indicating functional
specialization (LNCaP and DU145) or cooperation (PC3) among members of miR-130~301b cluster in PCa cell lines. e Invasion assay following anti-miR
knockdown of miR-130b or miR-301b using Matrigel coated Boyden chamber assay in LNCaP and PC3 cells, 72 h post-transfection. f, g Transcript levels
of CASP3 and KI67 in LNCaP and DU145 cells, respectively, 72 h after anti-miRNAs transfection. h mRNA expression of selected genes involved
in cell cycle, apoptosis and invasion in PC3 cells transfected with anti-miRNAs, indicating that both miR-130b and miR-301b knockdown decreased the
expression of Caspases (3, 8 and 9) and critical cell cycle check-point regulators. i Representative Western blots for CD44 and p27. All data are presented
as mean of three independent experiments ± s.d. (*p < 0.05, **p < 0.01, ***p < 0.001)
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genes CDKN2A (p16) and, more dramatically, CDKN2B
(p15) (Fig. 4e), alongside with downregulation of
LMNB1, a marker of cellular senescence (Fig. 4e), which
was confirmed at protein level (Fig. 4h). Nevertheless,
increased β-galactosidase (GLB1) mRNA levels were
only apparent upon miR-130b expression (Fig. 4e). Glo-
bally, the opposite trend was observed after endogenous
miR-130b or miR-301b depletion (Fig. 4f–h), although a
few exceptions were apparent, including CDK2 down-
regulation, at transcript level.
Formation of senescence-associated heterochromatic
foci (SAHF), specifically enriched for H3K9me3, has been
implicated in cellular senescence. Interestingly, following
pre-miR-130b transfection, an increase in H3K9me3 was
depicted, whereas anti-miR-130b and anti-miR-301b
transfections were associated with H3K9me3 decrease
(Fig. 4h).
In TCGA dataset (Additional file 2: Figure S3), overex-
pression of LMNB1 (p = 3.32 × 10−10) and down-regulation
of CDKN2B (p = 0.000218) was depicted in PCa tissue
samples, mimicking to some extent the pattern observed
following endogenous miR-130b or miR-301b depletion.
Nevertheless, whether LMNB1 reduction is caused by
senescence or is promoted by a direct interaction of miR-
130b or miR-301b with LMNB1-3′ UTR (Additional file 2:
Figure S7) remains unanswered.
miR-130b~301b induces SASP expression
The secretome of senescent cells is complex, consisting
of a range of cytokines, chemokines and proteases,
among others. To further confirm our previous findings,
we sought to analyse some elements of the senescence-
associated secretory phenotype (SASP), as these consti-
tute phenotypic and molecular markers of senescence
[14]. Thus, MMP1, MMP10, CCL20, IL1A, IL1B, IL6 and
IL8 expression was assessed. Globally, miR-130b or
miR-301b overexpression associated with increased ex-
pression of all genes tested, whereas anti-miR-130b or
anti-miR-301b transfection associated with decreased
MMP1, MMP10 and CCL20 expression, alongside with
IL1A, IL1B and IL6 overexpression, although at a much
smaller magnitude compared to miR-130b or miR-301b
overexpression (Fig. 5a, b).
In TCGA dataset, PCa tissue samples displayed signifi-
cantly lower IL1A, IL1B and IL6 expression levels
compared to normal prostate tissues (Additional file 2:
Figure S3).
Fig. 3 miR-130b and miR-301b overexpression attenuate malignant phenotype of PC3 cells. a Cell viability measured by MTT assay indicates that
transfection of pre-miR-130b and pre-miR-301b significantly decreased cell viability compared to pre-miR-NC transfected cells. b Either pre-miR-130b or
pre-miR-301b significantly increased the relative apoptosis levels as determined by the phosphatidylserine-based assay. c Cell cycle analysis of PC3 control
cells (pre-miR-NC) and PC3 overexpressing pre-miR-130b or pre-miR-301b, indicate that both miR-130b and miR-301b significantly induce cell cycle arrest
at S-phase and miR-130b also causes G2/M arrest. d Invasion assay in PC3 cells transfected with the pre-miRNAs 72 h before plating in Matrigel-coated
Boyden chambers. e mRNA expression levels of selected genes involved in apoptosis, cell cycle and invasion support that miR-130b and
miR-301b cooperatively reverse the acquisition of malignant features of PC3 cells. f Western blot for p21, p27 and CD44 in PC3 cells,
depicting selected gene overexpression upon miR-130b or miR-301b overexpression. All data are presented as mean of three independent
experiments ± s.d. (*p < 0.05, **p < 0.01, ***p < 0.001)
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SASP activation is induced by DNA damage
In senescent cells, the control of secretome is achieved
at many levels, from transcriptional regulation to auto-
crine feedback loops, but persistent DNA damage
response (DDR) appears to be critical for regulation of
SASP [15]. We thus hypothesized that miR-130b and
miR-301b might influence DNA damage responses and
genomic instability during senescence. Upon pre-miR-
130b or pre-miR-301b overexpression in PC3 cells, a sig-
nificant increase in DNA damage was depicted, using
the comet assay (Fig. 6a, b), especially in tail moment
(an index of induced DNA damage) and in the percent-
age of DNA in the tail. Subsequently, expression of
genes involved in DDR was evaluated and a significant
increase in two DNA damage inducible transcripts,
DDIT3 (that positively regulates IL6 and IL8) and
DDIT4 was found (Fig. 6c). Moreover, ATR, a DNA-
damage detector, was also upregulated. Strikingly, the
growth arrest and DNA-damage-inducible proteins
GADD45A and GADD45B were significantly overex-
pressed, as well as RAD9A and RAD17 (Fig. 6c).
Conversely, PCNA (a cell proliferation marker) was
among the downregulated genes.
Discussion
The intense research on the epigenetics field led to the
discovery that genes encoding miRNAs were epigeneti-
cally silenced through DNA methylation [1].
Because the miR-130b~301b cluster ranked first
among all hypermethylated miRNA promoters in our
dataset and, to the best of our knowledge, had not been
previously reported in PCa, it was selected for subse-
quent validation and functional characterization. Pyrose-
quencing of a large number of primary PCa and normal
prostate tissues, confirmed that miR-130b~301b cluster
promoter methylation levels were significantly higher in
the former, whereas the opposite was apparent for
expression levels of both miRNAs, thus prompting an
Fig. 4 Modulation of miR-130b and miR-301b induces cell senescence. Cell area (a) and sphericity (b) were increased upon miR-130b or miR-301b
overexpression and compared to the pre-miR-NC transfected PC3 cells. Cell area (c) and sphericity (d) decreased with anti-microRNAs knockdown of
miR-130b or miR-301b, indicating a more fibroblast-like phenotype. e RT-qPCR confirms transcriptional signature associated with promotion of cellular
senescence after forced expression of miR-130b or miR-301b. f attenuation of senescent phenotype following inhibition of endogenous levels of each
miRNA. h Western blot shows that LMNB1 levels are downregulated when miR-130b or miR-301b are overexpressed, concomitantly with locus-specific
H3K9me3 increase. All data are presented as mean of three independent experiments ± s.d. (*p < 0.05, **p < 0.01, ***p < 0.001)
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Fig. 5 miR-130b and miR-301b overexpression dramatically alters SASP expression in PC3 cells. a Comparing miR-130b or miR-301b overexpression
with pre-miR-NC control, a global increase in mRNA levels of most SASP-related genes was depicted. This signature suggests that miR-130b or
miR-301b-induced SASP reinforces senescence through autocrine mechanisms. b Comparison of miR-130b or miR-301b endogenous blockade
with anti-miR-NC control revealed a decrease (e.g. MMP10) or minimal increase (e.g. IL1A) in mRNA expression of some genes. This suggests
paracrine activity of SASP when miR-130b or miR-301b are inhibited in prostate cancer cells. All data are presented as mean of three independent
experiments ± s.d. (*p < 0.05, **p < 0.01, ***p < 0.001)
Fig. 6 miR-130b and miR-301b impair DNA-damage signalling pathway. a Comet assay immunofluorescence images of PC3 cells transfected with
pre-miRNAs and counterstained with Syber Green, depicting DNA-damage associated morphology. b Graphic representation of parameters analysed in
the assay, supporting that both miR-130b and miR-301b overexpression induce DNA damage in PC3 cells. c RT-qPCR evaluation of multiple genes
involved in DNA-damage response pathway. All data are presented as mean of three independent experiments ± s.d. (*p < 0.05, **p < 0.01, ***p < 0.001)
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association between aberrant promoter methylation and
expression downregulation in PCa. This was further
confirmed in vitro as PCa cell lines disclosed increased
expression levels after exposure to a demethylating
agent, either alone or in combination with TSA. Import-
antly, these findings are comparable to those reported
for miR-193b, miR-34b~34c and miR-23b~27b~24-1
cluster [16–18], confirming that aberrant promoter
methylation is, indeed, the mechanism underlying miR-
130b~301b cluster downregulation in PCa.
Concerning the functional characterization of these
findings, it should be emphasized that miR-130b and
miR-301b are members of a miRNA family which is
deregulated in several cancer types, acting either as
onco-miRs or tumour-suppressive miRs. Indeed, a
tumour-suppressive role for miR-130b in PCa has been
proposed (although the mechanism underlying its down-
regulation was not disclosed), counteracting metastasis
formation through MMP2 downregulation [19]. Never-
theless, another report implicated miR-130b in tumori-
genic reprogramming of adipose tissue-derived stem
cells in PCa patients, acting as oncomir [20]. Further-
more, the role of miR-301b in PCa remains elusive,
although it appears to be induced under hypoxia and
target NDRG2 [21, 22]. Interestingly, the functional
assays confirmed the tumour-suppressive action of miR-
130b and miR-301b. In both cases, miRNA overexpres-
sion reduced cell viability, induced apoptotic cell death
and irreversibly activated the cell cycle arrest program
DNA damage-induced senescence.
Phenotypic alterations were supported at molecular
level, as restored expression of both miR-130b and miR-
301b significantly increased the expression of genes
acting as checkpoint sensors, required for effective
tumour suppression. It is not clear whether these alter-
ations directly result from miRNA-mRNA interactions
at 5′ UTR or promoter [23], or from the naive output of
tumour-suppression. It might be speculated that both
miR-130b and miR-301b interact with other regulatory
elements and consequently enhance transcription or
translation of those genes [23]. Indeed, it has been
hypothesized that many miRNAs have evolved to act not
as genetic switches of specific pathways or individual
targets but rather to modulate expression of large gene
networks [24]. Moreover, it should be recalled that due
to the seed sequence similarity among miRNAs of the
same family, targets from the same miRNAs cluster may
be shared, although specific targets might also exist, as
result of other base pairing determinants in addition to
seed sequence [25]. This may explain why restoration of
either miR-130b or miR-301b basically had the same
functional impact. Nonetheless, the magnitude of the
effect may be different, as demonstrated for several tar-
get genes, including Ki67 and CASP3. Thus, different
functional specialization of miR-130b and miR-301b is
proposed.
Our data suggest that miR-130b~301b cluster might
counteract malignant transformation of prostate epithe-
lial cells through impairment of EMT, favouring MET
instead. This was apparent not only morphologically, as
PC3 cells exhibited a more epithelial phenotype upon
miR-130b or miR-301b overexpression, but also at mo-
lecular level, through increased expression of several
genes, including CD44. Interestingly, CD44 downregula-
tion was depicted following transfection with anti-miR-
130b or anti-miR-301b. Decreased CD44 expression has
been associated with a more aggressive PCa phenotype,
due to its association with higher grade and pathological
stage, correlating with biochemical recurrence and
tumour relapse [26]. Our observations are in line with
these findings, although the mechanism by which the
miR-130b~301b cluster influences CD44 expression
requires clarification. Nevertheless, it should be empha-
sized that the impact of miR-130b and miR-301b on
EMT-related genes seems to differ, as illustrated by the
almost opposite expression patterns of TGFB3 and
WNT5A. Yet, because no double transfection experiments
were conducted (as all were transient transfections), the
net result of miR-130b~301b cluster downregulation can-
not be determined.
An interesting and novel finding was the link between
miR-130b~301b cluster and cellular senescence. This
process induces cell cycle and cell growth arrest, and
it may counteract tumour formation [27]. Accumula-
tion of DNA damage is a common basis for senes-
cence, preventing genomic instability [28]. Senescent
cells display cell size increase and a more flattened
shape, as well as increased p53, CDKN2A (p16),
CDKN1A (p21) and CDKN1B (p27) expression, and
LMNB1 downregulation [29, 30]. Remarkably, the
same gene expression pattern was observed upon
miR-130b or miR-301b overexpression, whereas miR-
130b or miR-301b depletion had the opposite effect,
suggesting that miR-130b or miR-301b downregula-
tion might allow for senescence bypass. Our observa-
tions are also in line with previous reports correlating
LMNB1 reduction (particularly from H3K9me3 re-
gions) and spatial repositioning of perinuclear hetero-
chromatin (H3K9me3-enriched) and SAHF formation
[31]. These findings are further supported by induc-
tion of SASP upon miR-130b or miR-301b overexpres-
sion. Interestingly, in oncogene-induced senescence
(OIS), SASP is regulated by persistent DDR [32, 33].
We found that miR-130b or miR-301b overexpression
stimulated the expression of genes involved in DDR as
well as in DNA repair, suggesting that miR-130b~301b
cluster downregulation might impair OIS and foster
malignant transformation of prostate cells.
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Conclusions
In conclusion, we found novel miRNAs deregulated
through aberrant promoter methylation in PCa. In par-
ticular, the miR-130b~301b cluster displays a tumour-
suppressive profile and its downregulation might fuel
malignant transformation and tumour progression
through facilitation of EMT and bypass of cellular
senescence.
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130b or (C) pre-miR-301b. The restoration of miR-130b or miR-301b
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